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ABSTRACT 
 
In the present study, we explored the role of CC chemokine receptor 5 (CCR5) in a murine 
model of chronic fungal asthma induced by an intrapulmonary challenge with Aspergillus 
fumigatus conidia (or spores). Airway hyperresponsiveness was significantly lower in A. 
fumigatus-sensitized mice lacking CCR5 (CCR5-/-) compared with similarly sensitized wild-
type (CCR5+/+) control mice at days 2, 21, 30, and 40 after the conidia challenge. CCR5-/- mice 
exhibited significantly less peribronchial T-cell and eosinophil accumulation and airway-
remodeling features, such as goblet cell hyperplasia and peribronchial fibrosis, compared with 
CCR5+/+ mice at these times after conidia. However, both groups of mice exhibited similar 
allergic airway disease at day 12 after the conidia challenge. In CCR5-/- mice at day 12, the 
allergic airway disease was associated with airway hyperresponsiveness, peribronchial allergic 
inflammation, and goblet cell hyperplasia. Immunoneutralization of RANTES/CCL5 in 
sensitized CCR5+/+ and CCR5-/- mice for 12 days after the conidia challenge significantly 
reduced the peribronchial inflammation and airway hyperresponsiveness in comparison with 
control wild-type and knockout mice at this time. These data demonstrate that functional CCR5 
and RANTES/CCL5 are required for the persistence of chronic fungal asthma in mice.  
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he CC chemokine receptor CCR5 is expressed in some  immune cells, including 
macrophages and T-cells, and this receptor has a major role in the chemotaxis and 
activation of the cells that express it (1, 2). The major ligand for CCR5 is regulated on T-
cell activation, normal T-cell expressed and secreted (RANTES/CCL5), but this receptor also 
binds macrophage inflammatory protein 1-alpha (MIP-1α/CCL3) and MIP-1β/CCL4 (3). 
Individuals who are homozygous for a 32-nucleotide deletion (delta 32) within the CCR5 
(CCR5∆32) gene largely remain uninfected despite extensive exposure to HIV-1 (4), whereas 
heterozygous individuals exhibit limited protection against HIV-associated disease progression 
(5). More recently, the presence of CCR5∆32 was associated with a reduced risk of developing 
   
severe rheumatoid arthritis (6) and asthma (7), although subsequent studies question the 
relationship between CCR5∆32 and asthma (8, 9). Originally, CCR5 was characterized as a 
surface marker of human T-cells producing Th1 cytokines (10), but CCR5 expression is not 
essential for differentiation of human Th1 cells (11). Other data has shown that distinctions 
between chemokine receptor expression on Th1 and Th2 cells may be absent in vivo (3, 12). 
 
There is considerable evidence that lung (13–17) and plasma (18) levels of RANTES/CCL5 are 
elevated in allergic asthmatic patients. Furthermore, elevations in RANTES/CCL5 persuasively 
correlate with eosinophil and T-cell recruitment into the airways of allergen-challenged 
asthmatics (15-17, 19-23). In addition, single-nucleotide polymorphisms in the proximal 
RANTES/CCL5 promoter have been identified (24, 25), and one polymorphism in particular has 
been associated with an increased susceptibility to both atopy and asthma (26). Although it has 
been shown that RANTES/CCL5 interaction with CCR5 promotes the selective migration of Th1 
cells in vitro (27-29), experimental studies using acute models of Th2-mediated allergic airway 
disease have shown that RANTES/CCL5 is the major eosinophil (30) and T-cell chemoattractant 
(31, 32) that consequently modulates airway hyperresponsiveness to nonspecific spasmogens 
such as methacholine (32). The pro-asthmatic and allergic effects of RANTES/CCL5 may be 
mediated through its other receptors: CCR1, CCR3, and to a lesser extent CCR4 (33–35). 
 
In light of the controversy regarding the role of CCR5 in the development of asthma and allergic 
airway disease, we investigated the consequences of CCR5 gene deletion in a murine model of 
chronic fungal asthma. In the present study, the role of RANTES/CCL5 and its receptor, CCR5, 
were examined in the context of chronic fungal asthma. We have shown previously that the 
pulmonary response to conidia in A. fumigatus-sensitized mice includes chronic airway 
hyperresponsiveness, goblet cell hyperplasia, and subepithelial fibrosis (36). In addition, we have 
observed that chemokine receptors exert prominent effects on the development and maintenance 
of the asthmatic disease in these mice. For example, A. fumigatus-sensitized mice lacking CCR1 
maintain airway hyperresponsiveness but do not exhibit persistent airway remodeling following 
a conidia challenge (37). Conversely, CCR2-/- mice failed to clear A. fumigatus conidia and as a 
result developed severe allergic airway disease (38). Fungus-induced allergic airway responses in 
CCR5-/- mice have not been reported previously, leading us to examine the response of these 
mice and their wild-type controls (CCR5+/+) to an intratracheal challenge of A. fumigatus 
conidia following pulmonary sensitization to soluble antigens of the same fungus. 
 
MATERIALS AND METHODS  
 
Mice 
 
CCR5 wild-type (+/+) mice (B6129F2/J) and CCR5 knockout (-/-) mice (B6129F2/J-
Cmkbr5tm1kuz) mice were purchased from Jackson Laboratories (Bar Harbor, ME) or derived 
from breeding stocks at the University of Michigan (courtesy of Gary Huffnagle). Both groups of 
mice were maintained under specific pathogen-free conditions in the University Laboratory for 
Animal Medicine facility at the University of Michigan Medical School. At 5 to 6 wks of age, 
male and female CCR5-/- and CCR5+/+ mice were sensitized to a commercially available 
preparation of soluble A. fumigatus antigens as previously described in detail (36). A. fumigatus-
   
sensitized CCR5+/+ and CCR5-/- mice then received 5.0 × 106 A. fumigatus conidia suspended 
in 30 µl of PBS tween 80 (0.1%, vol/vol) via the intratracheal route (36).  
 
Measurement of bronchial hyperresponsiveness 
 
Bronchial hyperresponsiveness in both groups of mice (n=4–7 mice/group) was assessed by 
using a Buxco plethysmograph (Buxco, Troy, NY) (36) at days 2, 12, 21, 30, and 40 after the 
conidia challenge. Briefly, sodium pentobarbital (Butler Co., Columbus, OH; 0.04 mg/g of 
mouse body weight) was injected into mice before their intubation and ventilation with a 
Harvard pump ventilator (Harvard Apparatus, Reno, NV) (36). After a baseline period of 5 min, 
the mouse received 1 µg of methacholine by tail-vein injection. Airway hyperresponsiveness was 
calculated via the division of the transpulmonary pressure by the change in inspiratory volume 
(36). Immediately following the assessment of airway hyperresponsiveness, the mouse was 
killed, a bronchoalveolar lavage (BAL) was performed by using 1 ml of normal saline, and 500 
µl aliquot of blood was removed from each mouse for analysis. Finally, whole lungs were 
dissected from each mouse and snap-frozen in liquid N2 or prepared for histological analysis (see 
below). 
 
Immunoneutralization of RANTES/CCL5 
 
We conducted immunoneutralization of RANTES/CCL5 by i.p. injection of 20 µg of purified 
anti-murine RANTES antibody at two-day intervals between day 0 and 12 after the conidia 
challenge: the biological half-life of the antibody is approximately 48 h. The amount of antibody 
was more than sufficient to neutralize systemic endogenous RANTES/CCL5. Goat anti-murine 
RANTES/CCL5 was prepared on contract with Lampire Biological Laboratories (Pipersville, 
PA) by using a 14-amino acid carboxyl-terminal peptide of murine RANTES/CCL5 kindly 
provided by B. Daugherty (Merck, Whitehouse Station, NJ). We determined antiserum titer to be 
>1:1 × 107 by direct ELISA and confirmed neutralization by inhibition of RANTES/CCL5-
elicited eosinophil chemotaxis. The antibody does not cross-react with other assayed murine 
recombinant cytokines and chemokines. As a control, preimmune, normal goat, purified IgG was 
used. The endotoxin content in anti-RANTES/CCL5 antibody and control IgG was typically 
below detection level (<0.05 EU/ml Pyrogent; BioWhittaker, Walkersville, MD). AHR was 
assessed at day 12 after conidia. 
 
Morphometric analysis of leukocyte accumulation in BAL samples 
 
We centrifuged the BAL samples at 2,000 rpm for 5 min and removed the supernatants. The 
pelleted cells were resuspended in 200 µl of normal saline and transferred to coded microscope 
slides via Cytospin (Shandon Scientific, Runcorn, U.K.). Each slide was stained with a Wright–
Giemsa differential stain, and the average number of each cell type—neutrophil, macrophage, 
eosinophil, or lymphocyte—was determined after counting a total of 10–20 high-powered fields 
(hpf; 1,000×) per slide. BAL cell counts are represented as the average number of a specific cell 
type per hpf. 
 
 
 
   
ELISA analysis 
 
Total IgE levels were measured in 1-µl aliquots of mouse serum. Murine RANTES/CCL5, 
C10/CCL6, eotaxin/CCL11, IL-4, and IFN-γ were determined in 50-µl aliquots of whole lung 
homogenates using a standardized sandwich ELISA technique (39). Nunc-immuno ELISA plates 
(MaxiSorpTM) were coated with the appropriate polyclonal capture antibody (R&D Systems, 
Minneapolis, MN) at a dilution of 1–5 µg/ml of coating buffer (in M: 0.6 NaCl, 0.26 H3BO4, 
0.08 NaOH; pH 9.6) overnight at 4˚C. The unbound capture antibody was washed away, and 
each plate was blocked with 2% BSA-PBS for 1 h at 37˚C. Each ELISA plate was then washed 
three times with PBS tween 20 (0.05%; vol/vol), and 50 µl of undiluted or diluted (1:10) whole 
lung homogenate was added to duplicate wells and incubated for 1 h at 37˚C. Following the 
incubation period, the ELISA plates were washed thoroughly and the appropriate biotinylated 
polyclonal detection antibody (3.5 µg/ml) was added. After washing the plates 45 min later, we 
added streptavidin-peroxidase (Bio-Rad Laboratories, Richmond, CA) to each well for 30 min, 
after which we thoroughly washed the plates again. A chromagen substrate solution (Bio-Rad 
Laboratories) was added, and optical readings at 492 nm were obtained by using an ELISA plate 
scanner. Recombinant murine chemokines, cytokines, or IgE were used to generate the standard 
curves from which the concentrations present in the samples were derived. The limit of ELISA 
detection for each cytokine was consistently above 50 pg/ml. Each ELISA was screened to 
ensure the specificity of each antibody used. The cytokine and immunoglobulin levels in each 
sample were normalized to total protein levels using the Bradford assay. 
 
Soluble collagen analysis 
 
We have observed previously that peribronchial fibrosis peaks at day 30 after a conidia challenge 
in A. fumigatus-sensitized mice (36). In the present study, soluble forms of collagen were 
measured in whole lung homogenates from both groups of mice using the Sircol Collagen 
Assay (Biocolor Ltd., Belfast, Ireland). This assay was developed from the Sirius Red-based 
histochemical procedure. The collagen levels in each sample were normalized to total protein 
levels by using the Bradford assay. 
 
Whole lung histological analysis 
 
Whole lungs from A. fumigatus-sensitized CCR5+/+ and CCR5-/- mice, before and after A. 
fumigatus conidia challenge, were dissected from the thoracic cavity, fully inflated with 4% 
paraformaldehyde, and placed in fresh paraformaldehyde for 24 h. Routine histological 
techniques were used to paraffin-embed the entire lung, and 5-µm sections of whole lung were 
stained with either hematoxylin and eosin (H&E) or periodic acid Schiff (PAS). We examined 
inflammatory infiltrates and structural alterations around blood vessels and airways by using 
light microscopy at a magnification of 200×. 
 
Statistical analysis 
 
All results are expressed as mean ± SE. We performed statistical analysis at each time point 
before and after the conidia challenge by using the unpaired Student’s t-test to calculate the two-
tailed P value; P < 0.05 was considered statistically significant. 
   
 
RESULTS 
 
Total IgE levels are greater in A. fumigatus-sensitized CCR5-/- mice 
before and at day 40 after an intratracheal challenge with conidia 
 
Previous studies have shown that the T-cell-dependent humoral response to a specific antigen 
challenge is enhanced significantly in CCR5-/- mice compared with CCR5+/+ mice (40). In the 
present study, serum levels of total IgE were increased significantly in CCR5-/- mice before and 
at day 40 after the conidia challenge compared with CCR5+/+ mice at the same time points (Fig. 
1). The greatest levels of serum IgE were detected in both groups of mice at day 12 after conidia, 
but serum IgE levels were not significantly different between the two groups of mice at this time, 
nor at days 2 or 21 after the conidia challenge (Fig. 1). The presence of total IgE in serum 
samples confirmed that CCR5-/- mice developed allergic responsiveness to soluble A. fumigatus 
antigens, but serum IgE levels were similar between the two groups at most times after the 
conidia challenge. 
 
Transient changes in airway hyperresponsiveness in A. fumigatus-sensitized 
CCR5+/+ and CCR5-/- mice following a challenge with conidia 
 
Airway hyperresponsiveness following a methacholine challenge is a persistent feature of 
chronic fungal asthma in mice (36). The sensitization of CCR5-/- and CCR5+/+ mice to A. 
fumigatus was not associated with a marked increase in airway resistance following 
methacholine administration (data not shown), but airway hyperresponsiveness to methacholine 
was observed in both groups after the introduction of conidia (Fig. 2). Whereas CCR5+/+ mice 
exhibited 6- to 15-fold increases in airway resistance above the baseline level (represented by a 
dashed line on Fig. 2) at all times after the conidia challenge, CCR5-/- exhibited pronounced 
airway hyperresponsiveness only at day 12 after the conidia challenge (Fig. 2). At days 2, 21, 30, 
and 40, methacholine-induced airway resistance was significantly lower in CCR5-/- mice when 
compared with CCR5+/+ mice at the same time after the conidia challenge. Taken together, 
these data showed that, in contrast to wild-type mice sensitized with A. fumigatus, the 
development of airway hyperresponsiveness was delayed and transitory in A. fumigatus-
sensitized CCR5-/- mice after a live conidia challenge.  
 
Temporal changes in RANTES/CCL5 during chronic fungal asthma 
 
Whole lung RANTES/CCL5 levels in both groups of mice during the course of chronic fungal 
asthma is summarized in Figure 3. It was apparent that the pattern of expression for this CC 
chemokine differed markedly between the groups. Immediately before the introduction of 
conidia (time = 0), RANTES/CCL5 levels were approximately 6-fold higher in whole lung 
samples from CCR5-/- mice compared with CCR5+/+ mice. At days 2 and 12 after the conidia 
challenge, both groups of mice exhibited similar levels of RANTES/CCL5. However, at all later 
times after the conidia challenge, whole lung samples from CCR5-/- mice contained significantly 
greater levels of RANTES/CCL5 compared with the appropriate wild-type control group (Fig. 
3). In contrast, whole lung levels of other putative CCR5 ligands such as MIP-1α/CCL3 and 
   
MIP-1β/CCL4 did not differ between the two groups of mice before, or at any time after, the 
conidia challenge (data not shown). 
 
Temporal changes in eosinophil chemoattractants C10/CCL6 
and Eotaxin/CCL11 during chronic fungal asthma 
 
Specific ELISA analysis of whole lung levels of eosinophil chemoattractants C10/CCL6 (Fig. 
4A) and eotaxin/CCL11 (Fig. 4B) revealed major time-dependent changes in the levels of these 
chemokines during the course of chronic fungal asthma in CCR5+/+ and CCR5-/- mice. Before 
conidia, whole lung levels of C10/CCL6 and eotaxin/CCL11 were significantly lower in CCR5-
/- mice compared with the wild-type controls. C10/CCL6 levels remained significantly lower in 
whole lung samples from CCR5-/- mice at days 2 and 12 after conidia compared with levels of 
this chemokine in similar samples from CCR5+/+ mice (Fig 4A). At day 21 after conidia, the 
opposite profile was observed in that whole lung levels of both eosinophil chemoattractants were 
increased significantly in CCR5-/- mice compared with CCR5+/+ mice. However, at later time 
points (days 30 and 40), no significant differences in whole lung levels of C10/CCL6 and 
eotaxin/CCL11 were observed between CCR5-/- and CCR5+/+ mice (Fig. 4A, B). These data 
highlighted CCR5-/- mice’s marked deficit in eosinophil chemoattractants before and at early 
times after the conidia challenge.  
 
Transient peribronchial inflammation in A. fumigatus-sensitized 
CCR5-/- mice following a challenge with conidia 
 
Figure 5 summarizes the temporal changes in peribronchial inflammation present in A. 
fumigatus-sensitized mice CCR5+/+ and CCR5-/- mice at various times after a conidia 
challenge. The histological picture immediately before the conidia challenge suggested that little 
peribronchial inflammation was present in either CCR5+/+ mice (Fig. 5A) or CCR5-/- mice (Fig. 
5B). At day 2 after conidia, both groups of mice exhibited pronounced perivascular 
inflammation; peribronchial inflammation was apparent in CCR5+/+ mice (Fig. 5C), but not in 
CCR5-/- mice (Fig. 5D). At day 12 after conidia, peribronchial inflammation was prominent in 
both groups of mice (Fig. 5E, F). However, it was interesting to note that eosinophils were 
almost completely lacking around the airways of CCR5-/- mice at this time. Histological analysis 
at day 21 after the conidia challenge revealed that peribronchial inflammation and peribronchial 
fibrosis (pink spindle-shaped cells) were prominent in CCR5+/+ mice (Fig. 5G), but neither of 
these features of allergic airway disease were observed in CCR5-/- mice (Fig. 5H). At day 40 
after conidia, peribronchial inflammation had by and large resolved in both groups (Fig. 5I, J). 
Thus, the histological features of chronic fungal asthma were apparent only in CCR5-/- mice at 
day 12 after the conidia challenge. 
 
Temporal changes in leukocyte numbers in bronchoalveolar lavage 
from A. fumigatus-sensitized CCR5-/- and CCR5+/+ mice following a conidia challenge 
 
Changes in leukocyte numbers in the BAL appear to reflect that intensity of the airway 
inflammatory response during chronic fungal asthma (36). Consistent with our previous findings 
(36), the neutrophil was the prominent leukocyte, comprising more than 50% of the cells present 
in the BAL of CCR5+/+ and CCR5-/- mice, at day 2 after the conidia challenge (Fig. 6). Also at 
   
this time, lymphocytes and eosinophils were significantly less abundant in BAL samples from 
CCR5-/- mice compared with CCR5+/+ mice. At day 12 after conidia, macrophages were 
observed in significantly higher numbers in CCR5-/- mice compared with CCR5+/+ mice (Fig. 
6). Lymphocyte, eosinophil, and neutrophil numbers were equivalent in both groups of mice at 
this time after the conidia challenge. However, lymphocyte and eosinophil numbers were again 
significantly lower at day 21 after conidia in CCR5-/- mice compared with corresponding BAL 
samples from CCR5+/+ mice (Fig. 6). At day 40 after conidia, lymphocytes remained 
significantly reduced in CCR5-/- mice. The number of eosinophils in both groups was so low 
that it is doubtful if this cell type had physiologic impact at this time point (Fig. 6). Thus, the 
migration of major leukocyte subsets into the airways appeared to be modulated in a time-
dependent manner by the absence of CCR5 during the course of chronic fungal asthma disease.  
 
Transient goblet cell hyperplasia in A. fumigatus-sensitized 
CCR5-/- mice following a challenge with conidia 
 
Figure 7 summarizes the temporal changes in goblet cell hyperplasia present in A. fumigatus-
sensitized mice CCR5+/+ and CCR5-/- mice at various times after a conidia challenge. Neither 
group of mice exhibited goblet cell hyperplasia before the conidia challenge (not shown). The 
histological picture at day 2 revealed that goblet cells were much more prominent in the 
CCR5+/+ group (Fig. 7A) than in the CCR5-/- groups (Fig. 7B). At day 12 after conidia, goblet 
cell hyperplasia was a prominent feature in CCR5+/+ mice (Fig. 7C) and CCR5-/- mice (Fig. 
7D). Histological analysis at day 21 after the conidia challenge revealed that goblet cells were 
prominent in the airways of CCR5+/+ mice (Fig. 7E), no evidence of goblet cell hyperplasia was 
observed in CCR5-/- mice (Fig. 7F). Similarly at day 40 after the conidia challenge, the airways 
of CCR5+/+ mice (Fig. 7G) contained goblet cells, whereas the airways of CCR5-/- mice did not 
(Fig. 7H). Thus, goblet cell hyperplasia was present only in CCR5-/- mice at day 12 after the 
conidia challenge. 
 
CCR5-/- mice exhibit significantly less peribronchial fibrosis 
than CCR5+/+ mice at day 30 after a conidia challenge 
 
Previous studies have shown that the peribronchial fibrotic process is most pronounced at day 30 
after a conidia challenge (36). In the present study, we examined the levels of collagen in whole 
lung homogenates from CCR5+/+ and CCR5-/- mice at day 30 after conidia (Fig. 8). At this 
time, total soluble collagen levels in A. fumigatus-sensitized mice were increased approximately 
10-fold above those in nonsensitized mice (dashed line Fig. 8). Total soluble collagen levels in 
whole lung homogenates from CCR5-/- mice were approximately 4-fold (P=0.0329) lower than 
collagen levels in CCR5+/+ mice. These findings suggested that pulmonary airway remodeling 
in the form of peribronchial fibrosis was impaired in CCR5-/- mice during chronic fungal 
asthma. 
 
Whole lung levels of IL-4 and IFN-γ in A. fumigatus-sensitized 
CCR5+/+ and CCR5-/- mice following a challenge with conidia 
 
Zhou et al. (40) have shown that IL-4 and IFN-γ synthesis by CCR5-/- T-cells is significantly 
enhanced compared with CCR5+/+ T-cells. In the present study, we examined whether the 
   
transient expression of fungal asthma in CCR5-/- mice was related to changes in IL-4 and IFN-γ. 
As shown in Figure 9, IL-4 (A) and IFN-γ (B) were similar in both groups before and at most 
times after conidia. The exceptions were observed at day 2 after conidia when whole lung 
homogenates from CCR5-/- mice contained significantly less immunoreactive IL-4 and IFN-γ 
(Fig. 9A, B, respectively). In addition, at day 40 after conidia, whole lung homogenates from 
CCR5-/- mice contained significantly less IL-4 than similar samples from CCR5+/+ mice (Fig. 
9A). Overall, it did not appear that differences in whole lung levels of IL-4 and IFN-γ accounted 
for the transient nature of the fungal asthma in CCR5-/- mice.  
 
Immunoneutralization of RANTES/CCL5 during the first 12 days 
after the conidia challenge moderated fungal asthma in CCR5+/+ and CCR5-/- mice 
 
The role of RANTES in the context of the CCR5-/- mouse was determined by 
immunoneutralization from day 0–12 after conidia challenge after which AHR was assessed and 
serum and lung samples were removed for analysis. Passive neutralization of RANTES/CCL5 
significantly reduced airway resistance in both CCR5+/+ and CCR5-/- mice (Figure 10). 
Histological analysis showed resolution of inflammation throughout the CCR5+/+ and CCR5-/- 
lungs after anti-RANTES treatment with clear reduction of eosinophil and lymphocyte 
accumulation around both airways and blood vessels (Fig. 11). The recruitment of lymphocytes 
and eosinophils to the airways of CCR5-/- mice at day 12 was RANTES/CCL5-dependent as 
revealed by the BAL leukocyte counts (Figure 12) of mice that received anti-RANTES/CCL5 
antibodies. This was presumably due to the ability of RANTES to bind an alternative receptor. 
Future studies are intended to clarify the identity of this alternative receptor. 
 
DISCUSSION 
 
CCR5 is a chemokine receptor for MIP-1α/CCL3, MIP-1β/CCL4, and RANTES/CCL5 (42) (3). 
A natural mutation in CCR5 exists and individuals who are homozygous for a 32-base pair 
deletion in the coding sequence of CCR5 (CCR5∆32) were found to be highly resistant to HIV 
infection (4) and potentially other chronic diseases such as asthma (7). In the present study, we 
examined the contribution of CCR5 and RANTES/CCL5 to the development and maintenance of 
chronic fungal asthma induced by A. fumigatus conidia in A. fumigatus-sensitized mice. 
Experimental studies using acute models of allergic airway disease have corroborated these 
clinical findings by showing that RANTES/CCL5 is a major eosinophil (30) and T-cell 
chemoattractant (31, 32) that consequently modulates airway hyperresponsiveness (32). The role 
of RANTES/CCL5 in allergic wild-type mice has been examined by using antibody 
immunoneutralization techniques, but a description of allergic airway disease in CCR5-/- mice 
has not been reported previously. We observed that the appearance of fungal asthma in A. 
fumigatus-sensitized CCR5-/- mice was transient; allergic airway disease was observed only at 
one of the four time points examined after the introduction of conidia. In addition, 
RANTES/CCL5 appeared to mediate this transient appearance of fungal asthma in A. fumigatus-
sensitized CCR5-/- mice, possibly through one or more of its alternative receptors—CCR1, 
CCR3, and CCR4. Taken together, these data suggest that CCR5 and RANTES/CCL5 are key 
contributors to the development and maintenance of chronic fungal asthma in mice.  
 
   
The compilation of previous studies of immune responses by CCR5-/- mice results in a complex 
and multi-layered schema in which the involvement of CCR5 depends on the nature of the 
pathogen (i.e., bacterial, viral, or fungal), the site of infection, and the background strain of the 
CCR5-/- mouse. For example, Zhou et al. (40) demonstrated that CCR5-/- mice (on an ICR 
background) shared similar developmental qualities with their wild-type counterparts. This study 
also showed that CCR5-/- mice exhibited a defect in the innate immune response necessary for 
clearing Listeria from the liver (but not lung and spleen), whereas T-cell-dependent delayed-type 
hypersensitivity reactions and humoral responses were enhanced markedly in these mice. These 
latter findings agree with data from the present study, which revealed that A. fumigatus-
sensitized CCR5-/- mice had significantly higher serum levels of IgE before the conidia 
challenge compared with CCR5+/+ mice at the same time. However, serum IgE levels in these 
mice were comparable in both groups at all other times, except day 40 after conidia. 
Nonsensitized CCR5-/- mice (on a C57BL/6Jx129/Ola background) effectively resisted 
pulmonary infection with Cryptococcus neoformans but were susceptible to brain infection due 
to a lack of leukocyte recruitment into the brain (43). CCR5-/- mice on the same genetic 
background appeared to be susceptible to the lethal effects of a primary pulmonary influenza 
infection; this response appeared to be related to a massive inflammatory response rather than the 
cytopathic effects of an increased viral burden (44). However, other studies suggest that CCR5-/- 
mice (on a C57BL/6x129/Ola background) effectively clear or contain systemic and pulmonary 
pathogens such as Leishmania donovani (45) without any apparent or persistent immune 
abnormality. In the present study, A. fumigatus conidia were rapidly cleared from the airways of 
A. fumigatus-sensitized CCR5-/- mice compared with similarly sensitized CCR5+/+ mice. Both 
macrophages and neutrophils are required for the clearance of A. fumigatus from the airways of 
mice (46, 47), and comparable or significantly increased (P≤ 0.05 compared with CCR5+/+ 
mice) numbers of both leukocyte populations were observed after the conidia challenge in A. 
fumigatus-sensitized CCR5-/- mice. Our previous studies showed that neutrophil recruitment was 
impaired severely following a conidia challenge in A. fumigatus-sensitized CCR2-/- mice, and 
consequently CCR2-/- mice retained the conidia and developed severe allergic disease (38). 
 
RANTES/CCL5 was discovered by subtractive hybridization as a T-cell-specific sequence (48). 
It was initially shown to be a major chemoattractant for monocytes, memory T-cells (49), and 
eosinophils (50) particularly after an intranasal or intrapulmonary allergen challenge (14, 19, 21, 
51) (52). Constitutive and induced expression of RANTES/CCL5 has been described in airway 
epithelial cells (53), fibroblasts (54) (55), endothelial cells (56), smooth muscle cells (57), and 
eosinophils (52). All of these cell types appear to contribute to the increased levels of this CC 
chemokine, detected in the airways of patients with atopic (17) and non-atopic (22) asthma. 
Although its appearance was delayed compared with the CCR5+/+ group, airway 
hyperresponsiveness to methacholine was expressed transiently at day 12 after the conidia 
challenge in A. fumigatus-sensitized CCR5-/- mice. The recruitment of lymphocytes and 
eosinophils into and around the airways of CCR5-/- mice at day 12 was RANTES/CCL5-
dependent (as revealed by the BAL leukocyte counts in the passive immunoneutralization of 
RANTES/CCL5), presumably through its ability to bind CCR1, CCR3, and/or CCR4 (58) (33). 
Analysis of the possible compensatory role of these alternative receptors for RANTES is the 
subject of ongoing studies.  
 
   
CCR5 is expressed abundantly on T-cells from non-asthmatics and mild asthmatics (2). 
Originally, CCR5 was characterized as a surface marker of human T-cells producing Th1 
cytokines, but CCR5 expression is not essential for differentiation of human Th1 cells (11). Th1 
cells appear to preferentially express CCR5 and CXCR3 whereas Th2 cells preferentially express 
CCR4 and, to a lesser extent, CCR3 (10). More recent data have shown that such chemokine 
receptor distinctions between Th1 and Th2 cells may not be present in vivo (12). CCR5-/- mice 
exhibit a defect in IFN-γ production during acute Leishmania donovani infection but enhance 
IFN-γ production during a chronic challenge with this intracellular microbe (45). These 
observations corresponded with our findings that whole lung levels of IFN-γ were similar or 
significantly higher (i.e., at day 2 after conidia) in CCR5-/- mice compared with CCR5+/+ mice. 
We also noted that IL-4 was similar or significantly lower (i.e., at days 2 and 40 after conidia) in 
CCR5-/- mice compared with their wild-type counterparts. The findings from the present study 
suggest that the Th cytokine profile in CCR5-/- mice does not shift dramatically during the 
development of chronic fungal asthma. 
 
Airway remodeling generally refers to the structural changes that occur in the asthmatic airway 
as a result of ongoing Th2 cytokine-mediated inflammation (59, 60). These changes include 
epithelial and goblet cell hyperplasia; smooth-muscle hypertrophy; and, in some cases, 
pronounced sub-epithelial fibrosis (61–63). All of these features are present at various times after 
the conidia challenge in A. fumigatus-sensitized mice (36). However, we noted in the present 
study that goblet cell hyperplasia was detected at day 12 only after conidia in A. fumigatus-
sensitized CCR5-/- mice. Total soluble collagen was measured at day 30 after the conidia 
challenge to coincide with the time of peak peribronchial fibrosis in this model (36). The 
immunoneutralization of RANTES/CCL5 did not prevent the appearance of goblet cells in the 
airways of CCR5-/- mice at day 12. However, peribronchial fibrosis in CCR5-/- mice was 
significantly decreased at day 30 after the conidia challenge compared with the CCR5+/+ mice at 
the same time, and RANTES/CCL5 neutralization decreased early (day 12) collagen deposition 
in both CCR5+/+ and CCR5-/- mice. Thus, the development of airway remodeling was 
dependent in part, but not in whole, on RANTES/CCL5 and CCR5 during chronic fungal 
asthma. 
 
In conclusion, the results from the present study demonstrate the major role of RANTES/CCL5 
and CCR5 in a chronic model of fungal asthma. Although the lack of CCR5 markedly restricted 
the development of fungal asthma, it was apparent that its major ligand could function in its 
absence. Such findings highlight the complexity of chemokine-chemokine receptor interactions 
during chronic diseases and suggest that limiting the expression or function of RANTES/CCL5, 
rather than antagonizing CCR5, may be a more successful strategy in the treatment of clinical 
asthma. 
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Figure 1. Serum IgE levels in A. fumigatus-sensitized C-C chemokine receptor-5 (CCR5) wild-type (+/+) and 
CCR5 knockout (-/-) mice before and during various times after A. fumigatus conidia challenge. Significant 
differences between the two groups were detected before and at day 40 after the conidia challenge. Total IgE was 
measured by using a specific ELISA as described in Materials and Methods. Data are expressed as mean ± SE; 
n = 4–7/group/time point. 
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Figure 2. Airway hyperresponsiveness in A. fumigatus-sensitized C-C chemokine receptor-5 (CCR5) wild-type 
(+/+) and CCR5 knockout (-/-) mice before and during various times after an intrapulmonary challenge with live 
A. fumigatus conidia. Peak increases in airway resistance or hyperresponsiveness (units = cm H2O/ml/s) were determined 
at each time point after the intravenous injection of methacholine. Values are expressed as mean ± SE; n = 4–7/group/time 
point. 
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Figure 3. RANTES/CCL5 levels in whole lung homogenates from A. fumigatus-sensitized C-C chemokine 
receptor-5 (CCR5) wild-type (+/+) and CCR5 knockout (-/-) mice before and during various times after a live A. 
fumigatus conidia challenge. Cytokine levels were measured by using a specific ELISA as described in Materials and 
Methods. Values are expressed as mean ± SE;  n = 4–7 mice/group/time point. 
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Figure 4. C10/CCL6 (A) and eotaxin/CCL11 (B) levels in whole lung homogenates from A. fumigatus-sensitized C-
C chemokine receptor-5 (CCR5) wild-type (+/+) and CCR5 knockout (-/-) mice before and during various times 
after a live A. fumigatus conidia challenge. Cytokine levels were measured by using a specific ELISA as described in 
Materials and Methods. Values are expressed as mean ± SE; n = 4–7 mice/group/time point. 
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Figure 5. Representative photomicrographs of hematoxylin and eosin-stained whole lung sections from A. 
fumigatus-sensitized C-C chemokine receptor-5 (CCR5) wild-type (+/+) and CCR5 knockout (-/-) mice before and 
during various times after a live A. fumigatus conidia challenge. Little evidence of peribronchial inflammation was 
observed in CCR5+/+ mice (A) and CCR5-/- mice (B) before the conidia challenge. At day 2 after conidia, CCR5+/+ 
mice (C) exhibited perivascular and peribronchial inflammation, whereas CCR5-/- mice (D) exhibited perivascular 
inflammation alone. At day 12 after conidia, intense peribronchial inflammation was observed in both groups of mice  
(E, F). At day 21 after conidia, peribronchial inflammation and fibrosis (note pink spindle-shaped cells around airways) 
were observed in CCR5+/+ mice (G), whereas neither feature was apparent in CCR5-/- mice (H). Total lymphocyte 
numbers in the CCR5+/+ BAL were increased over CCR5-/- mice at day 40 after conidia. However, this increase did not 
translate into conspicuous inflammatory differences when compared by photomicrograph with CCR5-/- mice (I, J). 
Original magnification was 200× for each photomicrograph. 
Fig. 6 
 
                                          
                          
Figure 6. Leukocyte counts in bronchoalveolar lavage (BAL) samples from A. fumigatus-sensitized C-C 
chemokine receptor-5 (CCR5) wild-type (+/+) and CCR5 knockout (-/-) mice at days 2, 12, 21, and 40 after a live A. 
fumigatus conidia challenge. BAL cells were dispersed onto microscope slides by using a cytospin; and eosinophils, 
neutrophils, T lymphocytes, and macrophages were stained differentially with Wright–Giesma stain. A minimum of 10–
20 high-powered fields (hpf) was examined in each cytospin. Values are expressed as the mean number of each cell type 
per hpf ± SE. 
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Figure 7. Representative photomicrographs of periodic acid Schiff (PAS)-stained whole lung sections from A. 
fumigatus-sensitized C-C chemokine receptor-5 (CCR5) wild-type (+/+) and CCR5 knockout (-/-) mice before, and 
at various times after, a live A. fumigatus conidia challenge. At day 2 after conidia, goblet cells were apparent in the 
airways of CCR5+/+ mice (A), whereas few goblet cells were observed in the airways of CCR5-/- mice (B). Goblet cells 
were prominent in the airways of CCR5+/+ mice at days 12 (C), 21 (E), and 40 (G) after conidia. Goblet cells were 
present in the airways of CCR5-/- mice at day 12 after conidia (D), but not at days 21 (F) and 40 (H). Original 
magnification was 200× for each photomicrograph. 
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Figure 8. Total collagen levels in whole lung homogenates from A. fumigatus-sensitized C-C chemokine receptor-5 
(CCR5) wild-type (+/+) and CCR5 knockout (-/-) mice at day 30 after a live A. fumigatus conidia challenge. Total 
collagen levels were measured as described in Materials and Methods. Values are expressed as mean ± SE;  
n = 4–7/group/time point. 
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Figure 10. Airway hyperresponsiveness in A. fumigatus-sensitized C-C chemokine receptor-5 (CCR5) wild-type 
(+/+) and CCR5 knockout (-/-) mice treated with normal goat serum (control) or anti-RANTES antibody after 
intrapulmonary challenge with live A. fumigatus conidia. Peak increases in airway resistance or hyperresponsiveness 
(units = cm H2O/ml/s) were determined at each time point after the intravenous injection of methacholine. Values are 
expressed as mean ± SE; n = 4–7/group/time point. 
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Figure 11. Representative photomicrographs of hematoxylin and eosin (H&E)-stained whole lung sections from A. 
fumigatus-sensitized C-C chemokine receptor-5 (CCR5) wild-type (+/+) and CCR5 knockout (-/-) mice treated with 
intraperitoneal injections of normal goat serum or anti-RANTES antibody at day 12 after a live A. fumigatus 
conidia challenge. Inflammation is apparent around both the vasculature and airways of the CCR5+/+ mice treated with 
NGS (A), whereas inflammation was observed predominantly around the vessels only of CCR5-/- mice (B). Interstitial 
inflammation was apparent in CCR5+/+ mice treated with anti-RANTES (C), whereas CCR5-/- mice showed clear 
reduction of interstitial, perivascular, and peribronchial cell infiltrates (D). Original magnification was 200× for each 
photomicrograph. 
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Figure 12. Leukocyte counts in bronchoalveolar lavage (BAL) samples at day 12 after a live A. fumigatus conidia 
challenge from sensitized C-C chemokine receptor-5 (CCR5) knockout (-/-) mice treated every 48 h from day 0–12 
with anti-RANTES antibody. BAL cells were dispersed onto microscope slides by using a cytospin; eosinophils, 
neutrophils, T lymphocytes, and macrophages were stained differentially with Wright–Giesma stain. A minimum of 10–
20 high-powered fields (hpf) was examined in each cytospin. Values are expressed as the mean number of each cell type 
per hpf ± SE. 
